| SPHDF Stock | | | USD 9.42 0.00 0.00% |
SVP
Mr. Oliver Strub was Senior Vice President, General Counsel, Secretary to the Board, Member of the Executive Management Board of Santhera Pharmaceuticals Holding Ltd since February 1, 2015. He is an experienced commercial lawyer, also responsible for the Companys general legal affairs, insurances, trademarks, human resources and IT since 2015.
| Age | 60 |
| Tenure | 10 years |
| Phone | 41 61 906 89 50 |
| Web | https://www.santhera.com |
Strub joined Santhera in 2006 as General Counsel, shortly before the Company listed its shares on the SIX. From 1995 to 2006, he was with Ciba Geigy, then Ciba Specialty Chemicals, both Basel, Switzerland, where he was Head Corporationrationrationrate Law and Chief Compliance Officer. He holds a degree in law from Universitaet Basel.
Santhera Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
(0.4918) % which means that it has lost $0.4918 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(13.1615) %, meaning that it generated substantial loss on money invested by shareholders. Santhera Pharmaceuticals' management efficiency ratios could be used to measure how well Santhera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Santhera Pharmaceuticals Holding has accumulated 25.8
M in total debt. Santhera Pharmaceuticals has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Santhera Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Santhera Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Santhera Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Santhera to invest in growth at high rates of return. When we think about Santhera Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland. SANTHERA PHARMACEUTICALS operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs people. Santhera Pharmaceuticals Holding [SPHDF] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Santhera Pharmaceuticals Leadership Team
Elected by the shareholders, the Santhera Pharmaceuticals' board of directors comprises two types of representatives: Santhera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santhera. The board's role is to monitor Santhera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Santhera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santhera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eva Kalias, Head Communications | |
| Shabir MD, Chief Officer | |
| FCMA CGMA, Chief Officer | |
| Thomas Meier, CEO and Head of the Executive Management Team | |
| Dario Eklund, Chief Officer | |
| Gnther Metz, Head VP | |
| Neville MD, Head Management | |
| Sarah HolmesKlotz, Head Culture | |
| Oliver Strub, Sr. VP, General Counsel and Secretary | |
| Marc Schrader, Head Operations | |
Santhera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santhera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Santhera Pink Sheet
Santhera Pharmaceuticals financial ratios help investors to determine whether Santhera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santhera with respect to the benefits of owning Santhera Pharmaceuticals security.